

Joe Lombardo
Governor

Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**

DIVISION OF HEALTH CARE FINANCING AND POLICY

Helping people. It's who we are and what we do.



Stacie Weeks,
JD MPH
Administrator

Drug Utilization Review

Board Meeting Minutes

Date of Meeting: Thursday, April 20, 2023

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP),
Drug Use Review Board

Agenda Item	Record	Notes																														
1. Call to Order and Roll Call	<p>It was announced the meeting is being recorded.</p> <p>Chairperson Wheeler called the meeting to order at 1:05 p.m. on April 20, 2023.</p> <p>Chairperson Wheeler took the roll.</p> <table> <tr> <td></td><td>Present</td><td>Absent</td></tr> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Canty, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Rebecca Sparks, PA-C</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> </table>		Present	Absent	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>DHCFP Staff Present were as follows:</p> <ul style="list-style-type: none"> • Griffin, Karen, Senior Deputy Attorney General (SDAG) • Olsen, David, Chief of Pharmacy Services • Gudino, Antonio, Manager of Pharmacy Services • Clemons, Roshanda, Medical Director • Berntson, Kindra, Social Services Program Specialist II (SSPS II), Pharmacy Unit • Flowers, Ellen, Program Officer I, Pharmacy Unit <p>Magellan Rx Staff Present were as follows:</p> <ul style="list-style-type: none"> • Mishra, Raj, Pharm.D., Clinical Account Manager • Kim, James, Pharm.D., Dir. Clinical Account Services
	Present	Absent																														
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
• Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
• Brain Le, DO	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														

		<ul style="list-style-type: none">• Martinez, Chris, Sr. Business Analyst• Killpack, Andy, Pharm.D., Dir. Specialty Clinical Solutions <p>Managed Care Organization representatives present were as follows:</p> <ul style="list-style-type: none">• Lim, Luke, Pharm.D., Anthem• Bitton, Ryan, Pharm.D., Health Plan of Nevada• Miro, Trashelle, Pharm.D., Silver Summit Health Plan• Tran, Jimmy, Pharm.D., Molina Healthcare <p>The public attendee list is included as Attachment A.</p> <p>Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list’s accuracy is not assured.</p>								
2. General Public Comment	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.									
3. Administrative										
a. For Possible Action: Review and Approve Meeting Minutes from January 19, 2023.	<p>Board Member Netochi moved to approve the minutes as presented, and Board Member England seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>							

	<ul style="list-style-type: none"> • Netochi Adeolokun, Pharm.D., Vice Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Mark Canty, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Jessica Cate, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Rebecca Sparks, PA-C <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
b. Status Update by DHCFP	<p>Chief of Pharmacy Services David Olsen provided five announcements.</p> <ul style="list-style-type: none"> • The 82nd Legislative Session is currently underway. Value legislature typically only meets on odd number of years. This session is currently scheduled to end on June 6th. • Beginning July 1st of 2023 providers should begin contacting Magellan to obtain prior authorization for specific drugs for the Fee-for-Service recipients with date of service on or after July 1st. Providers will be able to complete the prior authorization process through either web or phone. Prior authorization will be required for medical specialty drugs when they are administered in the following places of service: physicians' offices, patient homes or outpatient facilities. Also, in addition to the prior authorization program, there will be a fee schedule for physician administered drugs starting in June. Please check the rates page on the DFCHP website for more information. If there any questions, please feel welcome to contact the Nevada Medicaid pharmacy services team at the RX Info e-mail listed on the agenda, it is rxinfo@dhcfp.nv.gov. • We do have a notable staff change to report in the division. Doctor Antonina Capurro was serving as the Deputy Administrator over Medical Programs, which included the pharmacy services. She left the division at the end of last month. The pharmacy unit is now directly reporting to Stacie Weeks, 	

	who is the Administrator for the division. She is scheduled to attend future DUR Board Meetings.	
4. Clinical Presentations		
a. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Verkazia		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.	
ii. Presentation of utilization and clinical information.	Dr. Raj Mishra provided the clinical background and indications for Verkazia. Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Verkazia. <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.	
iv. Proposed adoption of updated prior authorization criteria.	Board Member Tran moved to approve the criteria as presented by Magellan, and Board Member Canty seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):	

	<div> <div> Yes No Abst. </div> <ul style="list-style-type: none"> Jennifer Wheeler, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Netochi Adeolokun, Pharm.D., Vice Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Mark Canty, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Jessica Cate, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> Rebecca Sparks, PA-C <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div>	
b. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Epidiolex and Ztalmy .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Jennifer Shear Director of Payer Value and Outcomes with Jazz Pharmaceuticals.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra provided the clinical background and indications for Epidiolex and Ztalmy.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Epidiolex and Ztalmy.</p> <ul style="list-style-type: none"> Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. 	

	<ul style="list-style-type: none">• Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																																									
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																																									
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Canty moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
c. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Legembi .																																										
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.																																									

	Written public testimony from the Alzheimer's Association was sent.																													
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra provided the clinical background and indications for Legembi.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Legembi.</p> <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																													
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																													
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Castaneda moved to approve the criteria as presented by Magellan, and Board Member Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

	<ul style="list-style-type: none"> Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> Rebecca Sparks, PA-C <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
d. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Abraxane .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Dr. Janssen Sacro a Health Systems Liaison, Medical Affairs Scientist for Bristol-Myers Squibb.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Andy Killpack discussed the indications for Abraxane.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Abraxane.</p> <ul style="list-style-type: none"> Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>	
iv. Proposed adoption of updated prior authorization criteria.	Board Member Castaneda moved to approve the criteria as presented by Magellan, and Board Member Trans seconded the motion.	

	<p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <p>Dr. Mark Canty had to leave the meeting.</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
<p>e. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Bavencio.</p>																																										
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																									
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. Killpack discussed the indications for Bavencio.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Bavencio.</p>																																									

	<ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																																									
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																																									
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Castaneda moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
f. For Possible Action: Discussion and possible adoption of prior																																										

authorization criteria and/or quantity limits for Beovu .																										
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.																									
ii. Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Beovu. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization for Beovu. <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																									
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																									
iv. Proposed adoption of updated prior authorization criteria.	Board Member England moved to approve the criteria as presented by Magellan, and Board Member Sparks seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																							
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																							

	<ul style="list-style-type: none"> • Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Rebecca Sparks, PA-C <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
g. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Bevacizumab .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Bevacizumab.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Bevacizumab.</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>	

iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member Sparks moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																								
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
h.	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Darzalex .																																										
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>																																									
ii.	Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Darzalex.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Darzalex.</p>																																									

	<ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																																									
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																																									
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Tran moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
i. For Possible Action: Discussion and possible adoption of prior authorization criteria																																										

	and/or quantity limits for Darzalex Faspro .														
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>													
ii.	Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Darzalex Faspro.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Darzalex Faspro.</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 													
iii.	Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <ul style="list-style-type: none"> • No comments were made. 													
iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member Castaneda moved to approve the criteria as presented by Magellan, and Board Member Sparks seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.												
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>												
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>												

	<ul style="list-style-type: none"> • Mark Canty, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Jessica Cate, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Rebecca Sparks, PA-C <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
j. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Elaprase .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Elaprase.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Elaprase.</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	

iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																																									
iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member Castaneda moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Rebecca Sparks, PA-C</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																								
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
k.	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Eylea .																																										
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>																																									
ii.	Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Eylea.																																									

	<p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Eylea.</p> <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																																									
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																									
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Magellan, and Board Member Sparks seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
I. For Possible Action: Discussion and possible																																										

adoption of prior authorization criteria and/or quantity limits for Imfinzi .																		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.																	
ii. Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Imfinzi. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Imfinzi. <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																	
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																	
iv. Proposed adoption of updated prior authorization criteria.	Board Member Tran moved to approve the criteria as presented by Magellan, and Board Member Sparks seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>															

	<ul style="list-style-type: none"> • Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Jessica Cate, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Rebecca Sparks, PA-C <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
m. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for intravenous Immune Globulin (IVIG) .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for intravenous Immune Globulin (IVIG).</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of intravenous Immune Globulin (IVIG).</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	

iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																																									
iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Rebecca Sparks, PA-C</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																								
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
n.	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Jemperli .																																										
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>																																									
ii.	Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Jemperli.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder</p>																																									

	<p>and discussed the utilization of Jemperli.</p> <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																																									
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																									
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Tran moved to approve the criteria as presented by Magellan, and Board Member Sparks seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
o. For Possible Action: Discussion and possible adoption of prior																																										

authorization criteria and/or quantity limits for Kadcyla .																						
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.																					
ii. Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Kadcyla. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Kadcyla. <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																					
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																					
iv. Proposed adoption of updated prior authorization criteria.	Vice Chair Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																			
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																			
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																			
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																			
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																			

	<ul style="list-style-type: none"> Jessica Cate, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> Rebecca Sparks, PA-C <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
p. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Keytruda .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Keytruda.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Keytruda.</p> <ul style="list-style-type: none"> Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>	

iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																								
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
q.	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Libtayo .																																										
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>																																									
ii.	Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Libtayo.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Libtayo.</p>																																									

	<ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																																									
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																																									
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Castaneda moved to approve the criteria as presented by Magellan, and Board Member Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
5. DUR Board Requested Reports																																										
a. Opioid Reports:	<ul style="list-style-type: none">• Dr. Mishra presented opioid utilization reports.																																									
i. Opioid Trends	<ul style="list-style-type: none">• Dr. Lim presented opioid utilization reports.																																									

ii. Count of Claims iii. Med Trend iv. Top Members v. Top Prescribers vi. Top Pharmacy	<ul style="list-style-type: none"> • Dr. Bitton presented opioid utilization reports. • Dr. Miro presented opioid utilization reports. • Dr. Tran presented opioid utilization reports. <p>Chairperson Wheeler asked for comments from Board Members regarding Opioid Reports. The board discussed utilization and trends. No additional action taken or motions for investigative referrals.</p>	
b. Standard DUR Reports: i. Top 10 Classes by Amount Paid ii. Top 10 Classes by Claim Count iii. Quarterly ProDUR Paid Claims Saving Report iv. Retro DUR Initiatives	<ul style="list-style-type: none"> • Dr. Mishra presented Standard DUR Reports • Dr. Lim presented Standard DUR Reports. • Dr. Bitton presented Standard DUR Reports • Dr. Miro presented Standard DUR Reports • Dr. Tran presented Standard DUR Reports. 	
6. Closing Discussion		
a. Public Comment	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
b. For Possible Action: Date and location of the next meeting.	<p>Chairperson Wheeler stated the next meeting is scheduled for July 20, 2023.</p> <p>Location: Hilton Garden Inn Reno</p> <p>Meeting adjourned at 3:21 pm</p>	

Attachment A – Members of the Public in Attendance

Michael	Pazirandeh	Tammy	Buist	Mark	Rosenberg	Deb	Guay
Tina	Hartmann	Susan	Hertzberg	Jake	Matthews	Elyse	Monroy
Todd	Dickerson	Gina	Heinen	Joseph	Germain Jr.	Ronald	Matteotti
Fabiola	Garcia	Sara	Gao	Chris	Johnson	Maria	Reyes
Kevin	Chang	Gary	Parenteau	Jeana	Colabianchi	Amy	Hale
Lisa	Pulver	Bobby	White	Christy	Nguyen	Karen	Ou
Heather	Williamson	Jennifer	Shear	KayOnda	Bayo		
Janssen	Sacro	Joe	Germain	Geoffrey	Robinson		
Sung	Park	Chris	Santarone	Angela	Daughtridge		
Camille	Kerr	Jennifer	Davis	Mark	Paskett		

Attachment B – Submitted Written Comment

[Alzheimer's Association](#)